Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT02164084 Completed - Acne Vulgaris Clinical Trials

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

Start date: June 2014
Phase: Phase 1
Study type: Interventional

This study will identify how much (if any) drug is absorbed from the skin of subjects with acne vulgaris after topical application of SB204.

NCT ID: NCT02160678 Completed - Acne Vulgaris Clinical Trials

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Start date: May 2014
Phase: Phase 3
Study type: Interventional

To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams over that of the cream vehicle (placebo) in the treatment of acne vulgaris.

NCT ID: NCT02103816 Completed - Acne Scars Clinical Trials

The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study to evaluate the SmartLipo Triplex laser system along with the SideLaze800 hand piece in the treatment of Acne Scars.

NCT ID: NCT02103127 Completed - Acne Scars Clinical Trials

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars

Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to assess treatment of facial acne scars using the 755nm Alexandrite Laser with lens arrays.

NCT ID: NCT02100527 Withdrawn - Acne Vulgaris Clinical Trials

Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

Start date: April 2014
Phase: Phase 2
Study type: Interventional

This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.

NCT ID: NCT02073461 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.

NCT ID: NCT02073448 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Start date: March 2014
Phase: Phase 3
Study type: Interventional

This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.

NCT ID: NCT02066545 Completed - Acne Vulgaris Clinical Trials

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris

NCT ID: NCT02058628 Completed - Acne Vulgaris Clinical Trials

Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris

Start date: February 21, 2014
Phase: Phase 4
Study type: Interventional

This is a randomized, comparator-controlled, single-blind, parallel-group study. The current study proposes to compare a fixed-dose combination product containing 3% benzoyl peroxide (BPO) and 1% clindamycin against a cream containing 20% azelaic acid for the treatment of facial acne vulgaris. The results of the study will enable a better assessment of the safety and efficacy of the new dose regime (BPO 3% + clindamycin 1%) in comparison to a well established treatment. Based on the data more evidence based recommendations will be possible to improve the treatment of subjects with acne vulgaris. A total of 220 subjects will be enrolled and will have 5 study visits (Day 1, Weeks 2, 4, 8 and 12). The duration of the study will be over 12 weeks.

NCT ID: NCT02032407 Completed - Acne Vulgaris Clinical Trials

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

Start date: December 2013
Phase: Phase 4
Study type: Interventional

This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.